Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
New York Genome Center | RCV001256029 | SCV001432814 | uncertain significance | not provided | 2019-12-02 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001256029 | SCV002453106 | likely benign | not provided | 2024-04-10 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004659449 | SCV005163559 | uncertain significance | Inborn genetic diseases | 2024-04-05 | criteria provided, single submitter | clinical testing | The c.467A>G (p.Q156R) alteration is located in exon 3 (coding exon 1) of the RAI1 gene. This alteration results from a A to G substitution at nucleotide position 467, causing the glutamine (Q) at amino acid position 156 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004743373 | SCV005342031 | uncertain significance | RAI1-related disorder | 2024-04-16 | no assertion criteria provided | clinical testing | The RAI1 c.467A>G variant is predicted to result in the amino acid substitution p.Gln156Arg. To our knowledge, this variant has not been reported in the literature or in a large population database, indicating this variant is rare. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |